RxDoctor Payments Data

Elon Knoll, MD

Hematology & Oncology · Warren, MINPI 1275859704

Payments from drug & device makers

$1,285in general payments, 2019–2025

Across 40 payments — averaging $32.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$664
  • Johnson & Johnson$127
  • Amgen$67
  • Astellas Pharma US Inc$53
  • E.r. Squibb & Sons, L.L.C.$46
  • Sanofi$41
  • plus $288 from 13 others

What the payments were for

  • Food & beverage$50878%
  • Education$14522%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,285 in reported general payments places this provider in the 40th percentile of 282 hematology & oncology providers in Michigan.

See all hematology & oncology providers in Michigan

Medicare billing

Part B allowed, 2024
$83,948
Medicare patients
292
Services billed
789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib36$535,658
KisqaliRibociclib Succinate31$472,774
ImbruvicaIbrutinib28$442,999
CabometyxCabozantinib S-Malate17$431,359
TasignaNilotinib Hcl26$353,522
RevlimidLenalidomide27$344,872
TibsovoIvosidenib11$319,474
VerzenioAbemaciclib21$304,671
Lenalidomide21$299,209
PomalystPomalidomide11$257,369
CalquenceAcalabrutinib Maleate12$177,287
EliquisApixaban104$75,444
Abiraterone Acetate23$48,853
XareltoRivaroxaban29$26,486
Anastrozole267$11,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali, Tasigna$25$826,29657 claims
Exelixis Inc.Cabometyx$31$431,35917 claims
Bristol Myers SquibbRevlimid$15$344,87227 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$46$257,36911 claims
PfizerEliquis$36$75,444104 claims
Johnson & JohnsonXarelto$127$26,48629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 282 hematology & oncology providers in Michigan.

Other hematology & oncology in Warren

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →